nodes	percent_of_prediction	percent_of_DWPC	metapath
Norfloxacin—CYP3A4—bone cancer	0.444	1	CbGaD
Norfloxacin—TOP2A—Epirubicin—bone cancer	0.228	0.579	CbGbCtD
Norfloxacin—TOP2A—Doxorubicin—bone cancer	0.121	0.307	CbGbCtD
Norfloxacin—SLC22A6—Methotrexate—bone cancer	0.0353	0.0894	CbGbCtD
Norfloxacin—CYP3A4—Doxorubicin—bone cancer	0.00972	0.0246	CbGbCtD
Norfloxacin—TOP2A—Gastric Cancer Network 1—C21orf33—bone cancer	0.00519	0.0937	CbGpPWpGaD
Norfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—T—bone cancer	0.003	0.0542	CbGpPWpGaD
Norfloxacin—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00229	0.0414	CbGpPWpGaD
Norfloxacin—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00173	0.0312	CbGpPWpGaD
Norfloxacin—CYP2A6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00159	0.0286	CbGpPWpGaD
Norfloxacin—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00125	0.0226	CbGpPWpGaD
Norfloxacin—CYP1A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00118	0.0213	CbGpPWpGaD
Norfloxacin—CYP1A1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.00108	0.0195	CbGpPWpGaD
Norfloxacin—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000915	0.0165	CbGpPWpGaD
Norfloxacin—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000842	0.0152	CbGpPWpGaD
Norfloxacin—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000835	0.0151	CbGpPWpGaD
Norfloxacin—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000803	0.0145	CbGpPWpGaD
Norfloxacin—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.000765	0.0138	CbGpPWpGaD
Norfloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000753	0.0136	CbGpPWpGaD
Norfloxacin—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000744	0.0134	CbGpPWpGaD
Norfloxacin—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000736	0.0133	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000711	0.0128	CbGpPWpGaD
Norfloxacin—TOP2A—Doxorubicin—Epirubicin—bone cancer	0.000686	0.173	CbGdCrCtD
Norfloxacin—TOP2A—Idarubicin—Epirubicin—bone cancer	0.000686	0.173	CbGdCrCtD
Norfloxacin—TOP2A—Daunorubicin—Epirubicin—bone cancer	0.000686	0.173	CbGdCrCtD
Norfloxacin—CYP1A1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000681	0.0123	CbGpPWpGaD
Norfloxacin—TOP2A—Daunorubicin—Doxorubicin—bone cancer	0.000635	0.16	CbGdCrCtD
Norfloxacin—TOP2A—Idarubicin—Doxorubicin—bone cancer	0.000635	0.16	CbGdCrCtD
Norfloxacin—TOP2A—Epirubicin—Doxorubicin—bone cancer	0.000635	0.16	CbGdCrCtD
Norfloxacin—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000629	0.0113	CbGpPWpGaD
Norfloxacin—CYP1A1—Estrogen metabolism—CYP3A4—bone cancer	0.00062	0.0112	CbGpPWpGaD
Norfloxacin—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.000605	0.0109	CbGpPWpGaD
Norfloxacin—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000603	0.0109	CbGpPWpGaD
Norfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—bone cancer	0.000584	0.0105	CbGpPWpGaD
Norfloxacin—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000581	0.0105	CbGpPWpGaD
Norfloxacin—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.00058	0.0105	CbGpPWpGaD
Norfloxacin—CYP1A1—Xenobiotics—CYP3A4—bone cancer	0.00057	0.0103	CbGpPWpGaD
Norfloxacin—CYP1A1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000548	0.00989	CbGpPWpGaD
Norfloxacin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000547	0.00987	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000538	0.00971	CbGpPWpGaD
Norfloxacin—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000525	0.00948	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000508	0.00917	CbGpPWpGaD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.000503	0.00908	CbGpPWpGaD
Norfloxacin—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000435	0.00784	CbGpPWpGaD
Norfloxacin—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000414	0.00747	CbGpPWpGaD
Norfloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000407	0.00734	CbGpPWpGaD
Norfloxacin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.000405	0.00731	CbGpPWpGaD
Norfloxacin—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000395	0.00713	CbGpPWpGaD
Norfloxacin—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000379	0.00683	CbGpPWpGaD
Norfloxacin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000365	0.00659	CbGpPWpGaD
Norfloxacin—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000363	0.00656	CbGpPWpGaD
Norfloxacin—TOP2A—Mitotic G1-G1/S phases—DHFR—bone cancer	0.000354	0.00639	CbGpPWpGaD
Norfloxacin—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.00035	0.00631	CbGpPWpGaD
Norfloxacin—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000347	0.00625	CbGpPWpGaD
Norfloxacin—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000342	0.00617	CbGpPWpGaD
Norfloxacin—Hepatic failure—Epirubicin—bone cancer	0.000338	0.00334	CcSEcCtD
Norfloxacin—Eye pain—Epirubicin—bone cancer	0.000336	0.00333	CcSEcCtD
Norfloxacin—Vision blurred—Cisplatin—bone cancer	0.000336	0.00332	CcSEcCtD
Norfloxacin—Anaphylactoid reaction—Methotrexate—bone cancer	0.000335	0.00331	CcSEcCtD
Norfloxacin—Tremor—Cisplatin—bone cancer	0.000334	0.0033	CcSEcCtD
Norfloxacin—Osteoarthritis—Methotrexate—bone cancer	0.000325	0.00321	CcSEcCtD
Norfloxacin—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000324	0.00585	CbGpPWpGaD
Norfloxacin—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000323	0.00319	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000322	0.00582	CbGpPWpGaD
Norfloxacin—Dermatitis exfoliative—Epirubicin—bone cancer	0.000322	0.00318	CcSEcCtD
Norfloxacin—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.000321	0.0058	CbGpPWpGaD
Norfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—bone cancer	0.000321	0.00579	CbGpPWpGaD
Norfloxacin—Photosensitivity—Doxorubicin—bone cancer	0.00032	0.00316	CcSEcCtD
Norfloxacin—Leukopenia—Cisplatin—bone cancer	0.000319	0.00315	CcSEcCtD
Norfloxacin—Dermatitis bullous—Epirubicin—bone cancer	0.000318	0.00314	CcSEcCtD
Norfloxacin—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000318	0.00573	CbGpPWpGaD
Norfloxacin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000314	0.00567	CbGpPWpGaD
Norfloxacin—Anaphylactoid reaction—Epirubicin—bone cancer	0.000314	0.0031	CcSEcCtD
Norfloxacin—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000314	0.00566	CbGpPWpGaD
Norfloxacin—Hepatic failure—Doxorubicin—bone cancer	0.000313	0.00309	CcSEcCtD
Norfloxacin—Eye pain—Doxorubicin—bone cancer	0.000311	0.00308	CcSEcCtD
Norfloxacin—Hypoglycaemia—Epirubicin—bone cancer	0.000311	0.00308	CcSEcCtD
Norfloxacin—Irritability—Methotrexate—bone cancer	0.00031	0.00306	CcSEcCtD
Norfloxacin—Convulsion—Cisplatin—bone cancer	0.000309	0.00305	CcSEcCtD
Norfloxacin—TOP2A—Gastric Cancer Network 2—EGFR—bone cancer	0.000306	0.00552	CbGpPWpGaD
Norfloxacin—Ataxia—Methotrexate—bone cancer	0.000305	0.00302	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—ZW10—bone cancer	0.000305	0.0055	CbGpPWpGaD
Norfloxacin—Diplopia—Epirubicin—bone cancer	0.000304	0.003	CcSEcCtD
Norfloxacin—Osteoarthritis—Epirubicin—bone cancer	0.000304	0.003	CcSEcCtD
Norfloxacin—Myalgia—Cisplatin—bone cancer	0.000303	0.003	CcSEcCtD
Norfloxacin—Anxiety—Cisplatin—bone cancer	0.000302	0.00299	CcSEcCtD
Norfloxacin—Liver function test abnormal—Methotrexate—bone cancer	0.0003	0.00296	CcSEcCtD
Norfloxacin—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000298	0.00294	CcSEcCtD
Norfloxacin—Dermatitis bullous—Doxorubicin—bone cancer	0.000294	0.00291	CcSEcCtD
Norfloxacin—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000293	0.00528	CbGpPWpGaD
Norfloxacin—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000292	0.00289	CcSEcCtD
Norfloxacin—Anaphylactic shock—Cisplatin—bone cancer	0.000291	0.00287	CcSEcCtD
Norfloxacin—Oedema—Cisplatin—bone cancer	0.000291	0.00287	CcSEcCtD
Norfloxacin—Anaphylactoid reaction—Doxorubicin—bone cancer	0.00029	0.00287	CcSEcCtD
Norfloxacin—Hypoglycaemia—Doxorubicin—bone cancer	0.000288	0.00285	CcSEcCtD
Norfloxacin—Ataxia—Epirubicin—bone cancer	0.000286	0.00282	CcSEcCtD
Norfloxacin—Thrombocytopenia—Cisplatin—bone cancer	0.000285	0.00281	CcSEcCtD
Norfloxacin—Blood creatinine increased—Epirubicin—bone cancer	0.000285	0.00281	CcSEcCtD
Norfloxacin—Osteoarthritis—Doxorubicin—bone cancer	0.000281	0.00278	CcSEcCtD
Norfloxacin—Diplopia—Doxorubicin—bone cancer	0.000281	0.00278	CcSEcCtD
Norfloxacin—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000281	0.00507	CbGpPWpGaD
Norfloxacin—Hyperhidrosis—Cisplatin—bone cancer	0.000281	0.00278	CcSEcCtD
Norfloxacin—Liver function test abnormal—Epirubicin—bone cancer	0.00028	0.00277	CcSEcCtD
Norfloxacin—Eosinophilia—Methotrexate—bone cancer	0.000278	0.00275	CcSEcCtD
Norfloxacin—Orthostatic hypotension—Epirubicin—bone cancer	0.000277	0.00274	CcSEcCtD
Norfloxacin—Anorexia—Cisplatin—bone cancer	0.000277	0.00274	CcSEcCtD
Norfloxacin—Pancreatitis—Methotrexate—bone cancer	0.000275	0.00272	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000274	0.00495	CbGpPWpGaD
Norfloxacin—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000273	0.0027	CcSEcCtD
Norfloxacin—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000273	0.0027	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle—ZW10—bone cancer	0.000273	0.00492	CbGpPWpGaD
Norfloxacin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000265	0.00262	CcSEcCtD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000264	0.00477	CbGpPWpGaD
Norfloxacin—Ataxia—Doxorubicin—bone cancer	0.000264	0.00261	CcSEcCtD
Norfloxacin—Blood creatinine increased—Doxorubicin—bone cancer	0.000263	0.0026	CcSEcCtD
Norfloxacin—Dysphagia—Epirubicin—bone cancer	0.000262	0.0026	CcSEcCtD
Norfloxacin—Neutropenia—Methotrexate—bone cancer	0.000262	0.00259	CcSEcCtD
Norfloxacin—Paraesthesia—Cisplatin—bone cancer	0.000261	0.00258	CcSEcCtD
Norfloxacin—Eosinophilia—Epirubicin—bone cancer	0.00026	0.00257	CcSEcCtD
Norfloxacin—Liver function test abnormal—Doxorubicin—bone cancer	0.000259	0.00256	CcSEcCtD
Norfloxacin—Dyspnoea—Cisplatin—bone cancer	0.000259	0.00256	CcSEcCtD
Norfloxacin—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000258	0.00465	CbGpPWpGaD
Norfloxacin—Pancreatitis—Epirubicin—bone cancer	0.000257	0.00254	CcSEcCtD
Norfloxacin—TOP2A—Gastric Cancer Network 2—TP53—bone cancer	0.000257	0.00463	CbGpPWpGaD
Norfloxacin—Orthostatic hypotension—Doxorubicin—bone cancer	0.000257	0.00254	CcSEcCtD
Norfloxacin—Photosensitivity reaction—Methotrexate—bone cancer	0.000256	0.00253	CcSEcCtD
Norfloxacin—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000253	0.0025	CcSEcCtD
Norfloxacin—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000253	0.0025	CcSEcCtD
Norfloxacin—Decreased appetite—Cisplatin—bone cancer	0.000253	0.0025	CcSEcCtD
Norfloxacin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000251	0.00452	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00025	0.00451	CbGpPWpGaD
Norfloxacin—Drowsiness—Methotrexate—bone cancer	0.00025	0.00247	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00025	0.0045	CbGpPWpGaD
Norfloxacin—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000248	0.00245	CcSEcCtD
Norfloxacin—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000247	0.00446	CbGpPWpGaD
Norfloxacin—Renal failure—Methotrexate—bone cancer	0.000246	0.00243	CcSEcCtD
Norfloxacin—Neutropenia—Epirubicin—bone cancer	0.000245	0.00243	CcSEcCtD
Norfloxacin—Stomatitis—Methotrexate—bone cancer	0.000244	0.00241	CcSEcCtD
Norfloxacin—Conjunctivitis—Methotrexate—bone cancer	0.000243	0.0024	CcSEcCtD
Norfloxacin—Dysphagia—Doxorubicin—bone cancer	0.000243	0.0024	CcSEcCtD
Norfloxacin—TOP2A—Circadian rythm related genes—GNA11—bone cancer	0.000241	0.00434	CbGpPWpGaD
Norfloxacin—Eosinophilia—Doxorubicin—bone cancer	0.00024	0.00238	CcSEcCtD
Norfloxacin—TOP2A—Circadian rythm related genes—EZH2—bone cancer	0.00024	0.00432	CbGpPWpGaD
Norfloxacin—Photosensitivity reaction—Epirubicin—bone cancer	0.00024	0.00237	CcSEcCtD
Norfloxacin—Feeling abnormal—Cisplatin—bone cancer	0.00024	0.00237	CcSEcCtD
Norfloxacin—Haematuria—Methotrexate—bone cancer	0.000238	0.00236	CcSEcCtD
Norfloxacin—Pancreatitis—Doxorubicin—bone cancer	0.000238	0.00235	CcSEcCtD
Norfloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000238	0.00429	CbGpPWpGaD
Norfloxacin—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000237	0.00427	CbGpPWpGaD
Norfloxacin—Drowsiness—Epirubicin—bone cancer	0.000234	0.00231	CcSEcCtD
Norfloxacin—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000234	0.00421	CbGpPWpGaD
Norfloxacin—Agranulocytosis—Methotrexate—bone cancer	0.000233	0.00231	CcSEcCtD
Norfloxacin—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000232	0.00229	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000231	0.00417	CbGpPWpGaD
Norfloxacin—Renal failure—Epirubicin—bone cancer	0.00023	0.00227	CcSEcCtD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.00023	0.00415	CbGpPWpGaD
Norfloxacin—Body temperature increased—Cisplatin—bone cancer	0.00023	0.00227	CcSEcCtD
Norfloxacin—Neuropathy peripheral—Epirubicin—bone cancer	0.000229	0.00227	CcSEcCtD
Norfloxacin—Stomatitis—Epirubicin—bone cancer	0.000228	0.00226	CcSEcCtD
Norfloxacin—Jaundice—Epirubicin—bone cancer	0.000228	0.00226	CcSEcCtD
Norfloxacin—Conjunctivitis—Epirubicin—bone cancer	0.000227	0.00225	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000227	0.0041	CbGpPWpGaD
Norfloxacin—Neutropenia—Doxorubicin—bone cancer	0.000227	0.00225	CcSEcCtD
Norfloxacin—Hepatitis—Methotrexate—bone cancer	0.000224	0.00222	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000224	0.00405	CbGpPWpGaD
Norfloxacin—Haematuria—Epirubicin—bone cancer	0.000223	0.00221	CcSEcCtD
Norfloxacin—Photosensitivity reaction—Doxorubicin—bone cancer	0.000222	0.00219	CcSEcCtD
Norfloxacin—Agranulocytosis—Epirubicin—bone cancer	0.000218	0.00216	CcSEcCtD
Norfloxacin—Drowsiness—Doxorubicin—bone cancer	0.000217	0.00214	CcSEcCtD
Norfloxacin—Visual impairment—Methotrexate—bone cancer	0.000216	0.00214	CcSEcCtD
Norfloxacin—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000215	0.00212	CcSEcCtD
Norfloxacin—Hypersensitivity—Cisplatin—bone cancer	0.000214	0.00212	CcSEcCtD
Norfloxacin—Renal failure—Doxorubicin—bone cancer	0.000213	0.0021	CcSEcCtD
Norfloxacin—Erythema multiforme—Methotrexate—bone cancer	0.000212	0.0021	CcSEcCtD
Norfloxacin—Neuropathy peripheral—Doxorubicin—bone cancer	0.000212	0.0021	CcSEcCtD
Norfloxacin—Stomatitis—Doxorubicin—bone cancer	0.000211	0.00209	CcSEcCtD
Norfloxacin—Jaundice—Doxorubicin—bone cancer	0.000211	0.00209	CcSEcCtD
Norfloxacin—Conjunctivitis—Doxorubicin—bone cancer	0.00021	0.00208	CcSEcCtD
Norfloxacin—Hepatitis—Epirubicin—bone cancer	0.00021	0.00208	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—RFC1—bone cancer	0.00021	0.00378	CbGpPWpGaD
Norfloxacin—Tinnitus—Methotrexate—bone cancer	0.000209	0.00207	CcSEcCtD
Norfloxacin—Hypoaesthesia—Epirubicin—bone cancer	0.000209	0.00207	CcSEcCtD
Norfloxacin—Asthenia—Cisplatin—bone cancer	0.000209	0.00206	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle—TUBB4B—bone cancer	0.000207	0.00373	CbGpPWpGaD
Norfloxacin—Haematuria—Doxorubicin—bone cancer	0.000206	0.00204	CcSEcCtD
Norfloxacin—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000205	0.0037	CbGpPWpGaD
Norfloxacin—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000203	0.00366	CbGpPWpGaD
Norfloxacin—Visual impairment—Epirubicin—bone cancer	0.000202	0.002	CcSEcCtD
Norfloxacin—Agranulocytosis—Doxorubicin—bone cancer	0.000202	0.002	CcSEcCtD
Norfloxacin—Chills—Methotrexate—bone cancer	0.000201	0.00199	CcSEcCtD
Norfloxacin—Diarrhoea—Cisplatin—bone cancer	0.000199	0.00197	CcSEcCtD
Norfloxacin—Erythema multiforme—Epirubicin—bone cancer	0.000199	0.00196	CcSEcCtD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000196	0.00354	CbGpPWpGaD
Norfloxacin—Tinnitus—Epirubicin—bone cancer	0.000196	0.00194	CcSEcCtD
Norfloxacin—Erythema—Methotrexate—bone cancer	0.000195	0.00193	CcSEcCtD
Norfloxacin—Hepatitis—Doxorubicin—bone cancer	0.000194	0.00192	CcSEcCtD
Norfloxacin—Hypoaesthesia—Doxorubicin—bone cancer	0.000193	0.00191	CcSEcCtD
Norfloxacin—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000192	0.00346	CbGpPWpGaD
Norfloxacin—Dysgeusia—Methotrexate—bone cancer	0.000191	0.00189	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00019	0.00343	CbGpPWpGaD
Norfloxacin—Back pain—Methotrexate—bone cancer	0.000189	0.00187	CcSEcCtD
Norfloxacin—Chills—Epirubicin—bone cancer	0.000189	0.00186	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle—RFC1—bone cancer	0.000187	0.00338	CbGpPWpGaD
Norfloxacin—Visual impairment—Doxorubicin—bone cancer	0.000187	0.00185	CcSEcCtD
Norfloxacin—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000187	0.00337	CbGpPWpGaD
Norfloxacin—TOP2A—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000186	0.00336	CbGpPWpGaD
Norfloxacin—Vomiting—Cisplatin—bone cancer	0.000185	0.00183	CcSEcCtD
Norfloxacin—Vision blurred—Methotrexate—bone cancer	0.000184	0.00182	CcSEcCtD
Norfloxacin—Erythema multiforme—Doxorubicin—bone cancer	0.000184	0.00182	CcSEcCtD
Norfloxacin—Rash—Cisplatin—bone cancer	0.000183	0.00181	CcSEcCtD
Norfloxacin—Dermatitis—Cisplatin—bone cancer	0.000183	0.00181	CcSEcCtD
Norfloxacin—Erythema—Epirubicin—bone cancer	0.000183	0.00181	CcSEcCtD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000182	0.00328	CbGpPWpGaD
Norfloxacin—Tinnitus—Doxorubicin—bone cancer	0.000181	0.00179	CcSEcCtD
Norfloxacin—Flatulence—Epirubicin—bone cancer	0.00018	0.00178	CcSEcCtD
Norfloxacin—Tension—Epirubicin—bone cancer	0.000179	0.00177	CcSEcCtD
Norfloxacin—Dysgeusia—Epirubicin—bone cancer	0.000179	0.00177	CcSEcCtD
Norfloxacin—Nervousness—Epirubicin—bone cancer	0.000178	0.00176	CcSEcCtD
Norfloxacin—Back pain—Epirubicin—bone cancer	0.000177	0.00175	CcSEcCtD
Norfloxacin—Levofloxacin—CYP3A4—bone cancer	0.000177	0.509	CrCbGaD
Norfloxacin—Muscle spasms—Epirubicin—bone cancer	0.000176	0.00174	CcSEcCtD
Norfloxacin—Vertigo—Methotrexate—bone cancer	0.000176	0.00174	CcSEcCtD
Norfloxacin—Leukopenia—Methotrexate—bone cancer	0.000175	0.00173	CcSEcCtD
Norfloxacin—Chills—Doxorubicin—bone cancer	0.000174	0.00172	CcSEcCtD
Norfloxacin—Nausea—Cisplatin—bone cancer	0.000173	0.00171	CcSEcCtD
Norfloxacin—Vision blurred—Epirubicin—bone cancer	0.000172	0.0017	CcSEcCtD
Norfloxacin—Ciprofloxacin—CYP3A4—bone cancer	0.000171	0.491	CrCbGaD
Norfloxacin—Convulsion—Methotrexate—bone cancer	0.000169	0.00167	CcSEcCtD
Norfloxacin—Erythema—Doxorubicin—bone cancer	0.000169	0.00167	CcSEcCtD
Norfloxacin—Agitation—Epirubicin—bone cancer	0.000168	0.00166	CcSEcCtD
Norfloxacin—Flatulence—Doxorubicin—bone cancer	0.000167	0.00165	CcSEcCtD
Norfloxacin—Chest pain—Methotrexate—bone cancer	0.000166	0.00164	CcSEcCtD
Norfloxacin—Arthralgia—Methotrexate—bone cancer	0.000166	0.00164	CcSEcCtD
Norfloxacin—Myalgia—Methotrexate—bone cancer	0.000166	0.00164	CcSEcCtD
Norfloxacin—Tension—Doxorubicin—bone cancer	0.000166	0.00164	CcSEcCtD
Norfloxacin—Dysgeusia—Doxorubicin—bone cancer	0.000166	0.00164	CcSEcCtD
Norfloxacin—Nervousness—Doxorubicin—bone cancer	0.000164	0.00162	CcSEcCtD
Norfloxacin—Vertigo—Epirubicin—bone cancer	0.000164	0.00162	CcSEcCtD
Norfloxacin—Leukopenia—Epirubicin—bone cancer	0.000164	0.00162	CcSEcCtD
Norfloxacin—Back pain—Doxorubicin—bone cancer	0.000164	0.00162	CcSEcCtD
Norfloxacin—Muscle spasms—Doxorubicin—bone cancer	0.000163	0.00161	CcSEcCtD
Norfloxacin—TOP2A—Mitotic G1-G1/S phases—RB1—bone cancer	0.000162	0.00292	CbGpPWpGaD
Norfloxacin—Palpitations—Epirubicin—bone cancer	0.000162	0.0016	CcSEcCtD
Norfloxacin—Confusional state—Methotrexate—bone cancer	0.000161	0.00159	CcSEcCtD
Norfloxacin—Anaphylactic shock—Methotrexate—bone cancer	0.000159	0.00158	CcSEcCtD
Norfloxacin—Vision blurred—Doxorubicin—bone cancer	0.000159	0.00158	CcSEcCtD
Norfloxacin—Convulsion—Epirubicin—bone cancer	0.000158	0.00157	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000158	0.00285	CbGpPWpGaD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000157	0.00283	CbGpPWpGaD
Norfloxacin—Thrombocytopenia—Methotrexate—bone cancer	0.000156	0.00154	CcSEcCtD
Norfloxacin—Arthralgia—Epirubicin—bone cancer	0.000156	0.00154	CcSEcCtD
Norfloxacin—Chest pain—Epirubicin—bone cancer	0.000156	0.00154	CcSEcCtD
Norfloxacin—Myalgia—Epirubicin—bone cancer	0.000156	0.00154	CcSEcCtD
Norfloxacin—Agitation—Doxorubicin—bone cancer	0.000156	0.00154	CcSEcCtD
Norfloxacin—Anxiety—Epirubicin—bone cancer	0.000155	0.00153	CcSEcCtD
Norfloxacin—Hyperhidrosis—Methotrexate—bone cancer	0.000154	0.00152	CcSEcCtD
Norfloxacin—Dry mouth—Epirubicin—bone cancer	0.000152	0.00151	CcSEcCtD
Norfloxacin—Vertigo—Doxorubicin—bone cancer	0.000152	0.0015	CcSEcCtD
Norfloxacin—Anorexia—Methotrexate—bone cancer	0.000152	0.0015	CcSEcCtD
Norfloxacin—Leukopenia—Doxorubicin—bone cancer	0.000151	0.0015	CcSEcCtD
Norfloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000151	0.00272	CbGpPWpGaD
Norfloxacin—Confusional state—Epirubicin—bone cancer	0.000151	0.00149	CcSEcCtD
Norfloxacin—Palpitations—Doxorubicin—bone cancer	0.00015	0.00148	CcSEcCtD
Norfloxacin—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000149	0.00269	CbGpPWpGaD
Norfloxacin—Oedema—Epirubicin—bone cancer	0.000149	0.00148	CcSEcCtD
Norfloxacin—Anaphylactic shock—Epirubicin—bone cancer	0.000149	0.00148	CcSEcCtD
Norfloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000149	0.00269	CbGpPWpGaD
Norfloxacin—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000147	0.00266	CbGpPWpGaD
Norfloxacin—Convulsion—Doxorubicin—bone cancer	0.000147	0.00145	CcSEcCtD
Norfloxacin—Thrombocytopenia—Epirubicin—bone cancer	0.000146	0.00144	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000145	0.00144	CcSEcCtD
Norfloxacin—Hyperhidrosis—Epirubicin—bone cancer	0.000144	0.00143	CcSEcCtD
Norfloxacin—Insomnia—Methotrexate—bone cancer	0.000144	0.00143	CcSEcCtD
Norfloxacin—Chest pain—Doxorubicin—bone cancer	0.000144	0.00142	CcSEcCtD
Norfloxacin—Arthralgia—Doxorubicin—bone cancer	0.000144	0.00142	CcSEcCtD
Norfloxacin—Myalgia—Doxorubicin—bone cancer	0.000144	0.00142	CcSEcCtD
Norfloxacin—Anxiety—Doxorubicin—bone cancer	0.000144	0.00142	CcSEcCtD
Norfloxacin—Paraesthesia—Methotrexate—bone cancer	0.000143	0.00142	CcSEcCtD
Norfloxacin—Anorexia—Epirubicin—bone cancer	0.000142	0.00141	CcSEcCtD
Norfloxacin—Dyspnoea—Methotrexate—bone cancer	0.000142	0.00141	CcSEcCtD
Norfloxacin—Somnolence—Methotrexate—bone cancer	0.000142	0.0014	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000141	0.00254	CbGpPWpGaD
Norfloxacin—Dry mouth—Doxorubicin—bone cancer	0.000141	0.00139	CcSEcCtD
Norfloxacin—Dyspepsia—Methotrexate—bone cancer	0.00014	0.00139	CcSEcCtD
Norfloxacin—Confusional state—Doxorubicin—bone cancer	0.000139	0.00138	CcSEcCtD
Norfloxacin—Decreased appetite—Methotrexate—bone cancer	0.000139	0.00137	CcSEcCtD
Norfloxacin—Anaphylactic shock—Doxorubicin—bone cancer	0.000138	0.00137	CcSEcCtD
Norfloxacin—Oedema—Doxorubicin—bone cancer	0.000138	0.00137	CcSEcCtD
Norfloxacin—Fatigue—Methotrexate—bone cancer	0.000138	0.00136	CcSEcCtD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000137	0.00247	CbGpPWpGaD
Norfloxacin—CYP2A6—Biological oxidations—CYP3A4—bone cancer	0.000137	0.00247	CbGpPWpGaD
Norfloxacin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000136	0.00134	CcSEcCtD
Norfloxacin—TOP2A—Circadian rythm related genes—CDK4—bone cancer	0.000135	0.00244	CbGpPWpGaD
Norfloxacin—Thrombocytopenia—Doxorubicin—bone cancer	0.000135	0.00134	CcSEcCtD
Norfloxacin—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	0.000135	0.00244	CbGpPWpGaD
Norfloxacin—Insomnia—Epirubicin—bone cancer	0.000135	0.00133	CcSEcCtD
Norfloxacin—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	0.000135	0.00243	CbGpPWpGaD
Norfloxacin—Paraesthesia—Epirubicin—bone cancer	0.000134	0.00133	CcSEcCtD
Norfloxacin—Hyperhidrosis—Doxorubicin—bone cancer	0.000134	0.00132	CcSEcCtD
Norfloxacin—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	0.000133	0.00241	CbGpPWpGaD
Norfloxacin—CYP2A6—NRF2 pathway—GSTP1—bone cancer	0.000133	0.00241	CbGpPWpGaD
Norfloxacin—Dyspnoea—Epirubicin—bone cancer	0.000133	0.00132	CcSEcCtD
Norfloxacin—Somnolence—Epirubicin—bone cancer	0.000133	0.00131	CcSEcCtD
Norfloxacin—Anorexia—Doxorubicin—bone cancer	0.000132	0.0013	CcSEcCtD
Norfloxacin—Feeling abnormal—Methotrexate—bone cancer	0.000131	0.0013	CcSEcCtD
Norfloxacin—Dyspepsia—Epirubicin—bone cancer	0.000131	0.0013	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Methotrexate—bone cancer	0.00013	0.00129	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—DHFR—bone cancer	0.00013	0.00234	CbGpPWpGaD
Norfloxacin—Decreased appetite—Epirubicin—bone cancer	0.00013	0.00128	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00013	0.00234	CbGpPWpGaD
Norfloxacin—Fatigue—Epirubicin—bone cancer	0.000129	0.00127	CcSEcCtD
Norfloxacin—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000128	0.0023	CbGpPWpGaD
Norfloxacin—Constipation—Epirubicin—bone cancer	0.000128	0.00126	CcSEcCtD
Norfloxacin—Urticaria—Methotrexate—bone cancer	0.000127	0.00125	CcSEcCtD
Norfloxacin—Body temperature increased—Methotrexate—bone cancer	0.000126	0.00125	CcSEcCtD
Norfloxacin—Abdominal pain—Methotrexate—bone cancer	0.000126	0.00125	CcSEcCtD
Norfloxacin—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000126	0.00227	CbGpPWpGaD
Norfloxacin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000126	0.00124	CcSEcCtD
Norfloxacin—Insomnia—Doxorubicin—bone cancer	0.000125	0.00123	CcSEcCtD
Norfloxacin—Paraesthesia—Doxorubicin—bone cancer	0.000124	0.00123	CcSEcCtD
Norfloxacin—Dyspnoea—Doxorubicin—bone cancer	0.000123	0.00122	CcSEcCtD
Norfloxacin—Feeling abnormal—Epirubicin—bone cancer	0.000123	0.00122	CcSEcCtD
Norfloxacin—Somnolence—Doxorubicin—bone cancer	0.000123	0.00121	CcSEcCtD
Norfloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000122	0.00221	CbGpPWpGaD
Norfloxacin—Gastrointestinal pain—Epirubicin—bone cancer	0.000122	0.00121	CcSEcCtD
Norfloxacin—Dyspepsia—Doxorubicin—bone cancer	0.000122	0.0012	CcSEcCtD
Norfloxacin—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000121	0.00219	CbGpPWpGaD
Norfloxacin—Decreased appetite—Doxorubicin—bone cancer	0.00012	0.00119	CcSEcCtD
Norfloxacin—Fatigue—Doxorubicin—bone cancer	0.000119	0.00118	CcSEcCtD
Norfloxacin—Urticaria—Epirubicin—bone cancer	0.000119	0.00117	CcSEcCtD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000118	0.00213	CbGpPWpGaD
Norfloxacin—Constipation—Doxorubicin—bone cancer	0.000118	0.00117	CcSEcCtD
Norfloxacin—Body temperature increased—Epirubicin—bone cancer	0.000118	0.00117	CcSEcCtD
Norfloxacin—Abdominal pain—Epirubicin—bone cancer	0.000118	0.00117	CcSEcCtD
Norfloxacin—Hypersensitivity—Methotrexate—bone cancer	0.000118	0.00116	CcSEcCtD
Norfloxacin—CYP2A6—Biological oxidations—GSTP1—bone cancer	0.000117	0.00211	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000117	0.00211	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—DHFR—bone cancer	0.000116	0.0021	CbGpPWpGaD
Norfloxacin—Asthenia—Methotrexate—bone cancer	0.000114	0.00113	CcSEcCtD
Norfloxacin—Feeling abnormal—Doxorubicin—bone cancer	0.000114	0.00113	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Doxorubicin—bone cancer	0.000113	0.00112	CcSEcCtD
Norfloxacin—Pruritus—Methotrexate—bone cancer	0.000113	0.00112	CcSEcCtD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000112	0.00203	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Epirubicin—bone cancer	0.00011	0.00109	CcSEcCtD
Norfloxacin—Urticaria—Doxorubicin—bone cancer	0.00011	0.00108	CcSEcCtD
Norfloxacin—Abdominal pain—Doxorubicin—bone cancer	0.000109	0.00108	CcSEcCtD
Norfloxacin—Body temperature increased—Doxorubicin—bone cancer	0.000109	0.00108	CcSEcCtD
Norfloxacin—Diarrhoea—Methotrexate—bone cancer	0.000109	0.00108	CcSEcCtD
Norfloxacin—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000108	0.00195	CbGpPWpGaD
Norfloxacin—Asthenia—Epirubicin—bone cancer	0.000107	0.00106	CcSEcCtD
Norfloxacin—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000106	0.00192	CbGpPWpGaD
Norfloxacin—Pruritus—Epirubicin—bone cancer	0.000106	0.00104	CcSEcCtD
Norfloxacin—Dizziness—Methotrexate—bone cancer	0.000105	0.00104	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000105	0.00189	CbGpPWpGaD
Norfloxacin—Diarrhoea—Epirubicin—bone cancer	0.000102	0.00101	CcSEcCtD
Norfloxacin—CYP1A1—Biological oxidations—CYP3A4—bone cancer	0.000102	0.00184	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Doxorubicin—bone cancer	0.000102	0.00101	CcSEcCtD
Norfloxacin—Vomiting—Methotrexate—bone cancer	0.000101	0.001	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000101	0.00182	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000101	0.00182	CbGpPWpGaD
Norfloxacin—Rash—Methotrexate—bone cancer	0.000101	0.000994	CcSEcCtD
Norfloxacin—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000101	0.00181	CbGpPWpGaD
Norfloxacin—Dermatitis—Methotrexate—bone cancer	0.0001	0.000993	CcSEcCtD
Norfloxacin—Headache—Methotrexate—bone cancer	9.99e-05	0.000988	CcSEcCtD
Norfloxacin—Asthenia—Doxorubicin—bone cancer	9.91e-05	0.00098	CcSEcCtD
Norfloxacin—Dizziness—Epirubicin—bone cancer	9.87e-05	0.000976	CcSEcCtD
Norfloxacin—Pruritus—Doxorubicin—bone cancer	9.77e-05	0.000966	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle—CHEK2—bone cancer	9.71e-05	0.00175	CbGpPWpGaD
Norfloxacin—CYP1A2—Phase II conjugation—GSTP1—bone cancer	9.5e-05	0.00171	CbGpPWpGaD
Norfloxacin—Vomiting—Epirubicin—bone cancer	9.49e-05	0.000938	CcSEcCtD
Norfloxacin—Nausea—Methotrexate—bone cancer	9.47e-05	0.000937	CcSEcCtD
Norfloxacin—Diarrhoea—Doxorubicin—bone cancer	9.45e-05	0.000934	CcSEcCtD
Norfloxacin—Rash—Epirubicin—bone cancer	9.41e-05	0.00093	CcSEcCtD
Norfloxacin—Dermatitis—Epirubicin—bone cancer	9.4e-05	0.00093	CcSEcCtD
Norfloxacin—Headache—Epirubicin—bone cancer	9.35e-05	0.000924	CcSEcCtD
Norfloxacin—CYP3A5—Biological oxidations—GSTP1—bone cancer	9.23e-05	0.00166	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	9.2e-05	0.00166	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.2e-05	0.00166	CbGpPWpGaD
Norfloxacin—Dizziness—Doxorubicin—bone cancer	9.13e-05	0.000903	CcSEcCtD
Norfloxacin—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	9.1e-05	0.00164	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	9.08e-05	0.00164	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—NDUFA12—bone cancer	8.95e-05	0.00161	CbGpPWpGaD
Norfloxacin—Nausea—Epirubicin—bone cancer	8.87e-05	0.000877	CcSEcCtD
Norfloxacin—Vomiting—Doxorubicin—bone cancer	8.78e-05	0.000868	CcSEcCtD
Norfloxacin—TOP2A—Circadian rythm related genes—JUN—bone cancer	8.72e-05	0.00157	CbGpPWpGaD
Norfloxacin—CYP1A1—Biological oxidations—GSTP1—bone cancer	8.72e-05	0.00157	CbGpPWpGaD
Norfloxacin—Rash—Doxorubicin—bone cancer	8.71e-05	0.000861	CcSEcCtD
Norfloxacin—Dermatitis—Doxorubicin—bone cancer	8.7e-05	0.00086	CcSEcCtD
Norfloxacin—Headache—Doxorubicin—bone cancer	8.65e-05	0.000855	CcSEcCtD
Norfloxacin—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	8.6e-05	0.00155	CbGpPWpGaD
Norfloxacin—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	8.58e-05	0.00155	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	8.27e-05	0.00149	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—BRCA2—bone cancer	8.23e-05	0.00148	CbGpPWpGaD
Norfloxacin—Nausea—Doxorubicin—bone cancer	8.2e-05	0.000811	CcSEcCtD
Norfloxacin—CYP2A6—Metabolism—NDUFA12—bone cancer	8.2e-05	0.00148	CbGpPWpGaD
Norfloxacin—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	7.74e-05	0.0014	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	7.46e-05	0.00135	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—NT5C3A—bone cancer	7.41e-05	0.00134	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	7.14e-05	0.00129	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—CDK4—bone cancer	6.82e-05	0.00123	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—NT5C3A—bone cancer	6.8e-05	0.00123	CbGpPWpGaD
Norfloxacin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.62e-05	0.00119	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—CYP3A4—bone cancer	6.5e-05	0.00117	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—NDUFA12—bone cancer	6.47e-05	0.00117	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	6.41e-05	0.00116	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—NDUFA12—bone cancer	6.11e-05	0.0011	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—CDK4—bone cancer	6.1e-05	0.0011	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	6e-05	0.00108	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—RB1—bone cancer	5.93e-05	0.00107	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	5.86e-05	0.00106	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	5.86e-05	0.00106	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—TP53—bone cancer	5.76e-05	0.00104	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—GSTP1—bone cancer	5.56e-05	0.001	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	5.48e-05	0.000989	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—NT5C3A—bone cancer	5.36e-05	0.000967	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—RB1—bone cancer	5.31e-05	0.000957	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—NT5C3A—bone cancer	5.06e-05	0.000913	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—MDM2—bone cancer	4.52e-05	0.000816	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.29e-05	0.000774	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.23e-05	0.000763	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—NDUFA12—bone cancer	3.9e-05	0.000703	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—ENO2—bone cancer	3.25e-05	0.000586	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—NT5C3A—bone cancer	3.23e-05	0.000582	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—DHFR—bone cancer	3.01e-05	0.000544	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—NDUFA12—bone cancer	3.01e-05	0.000542	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—ENO2—bone cancer	2.98e-05	0.000537	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—GNA11—bone cancer	2.82e-05	0.000508	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—DHFR—bone cancer	2.76e-05	0.000498	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—TP53—bone cancer	2.6e-05	0.000468	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—GNA11—bone cancer	2.58e-05	0.000466	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CYP3A4—bone cancer	2.55e-05	0.000461	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—NT5C3A—bone cancer	2.49e-05	0.000449	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—ENO2—bone cancer	2.35e-05	0.000423	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CYP3A4—bone cancer	2.34e-05	0.000422	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—ENO2—bone cancer	2.22e-05	0.0004	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—GSTP1—bone cancer	2.18e-05	0.000394	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—DHFR—bone cancer	2.18e-05	0.000393	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—DHFR—bone cancer	2.06e-05	0.000371	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—GNA11—bone cancer	2.04e-05	0.000367	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—GSTP1—bone cancer	2e-05	0.000361	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—GNA11—bone cancer	1.92e-05	0.000347	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CYP3A4—bone cancer	1.85e-05	0.000333	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CYP3A4—bone cancer	1.74e-05	0.000315	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.73e-05	0.000313	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—GSTP1—bone cancer	1.58e-05	0.000285	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—GSTP1—bone cancer	1.49e-05	0.000269	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—ENO2—bone cancer	1.41e-05	0.000255	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—DHFR—bone cancer	1.31e-05	0.000237	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—GNA11—bone cancer	1.23e-05	0.000221	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—PTGS2—bone cancer	1.13e-05	0.000204	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CYP3A4—bone cancer	1.11e-05	0.000201	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.11e-05	0.0002	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—ENO2—bone cancer	1.09e-05	0.000197	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—PTGS2—bone cancer	1.04e-05	0.000187	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—DHFR—bone cancer	1.01e-05	0.000183	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—GSTP1—bone cancer	9.51e-06	0.000172	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—GNA11—bone cancer	9.46e-06	0.000171	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—PTGS2—bone cancer	8.18e-06	0.000148	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—PTGS2—bone cancer	7.72e-06	0.000139	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—GSTP1—bone cancer	7.34e-06	0.000132	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—PTGS2—bone cancer	4.92e-06	8.89e-05	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—PTGS2—bone cancer	3.8e-06	6.86e-05	CbGpPWpGaD
